Lilly Endowment Inc. Decreases Stake in Eli Lilly And Co (LLY)

Lilly Endowment Inc. lowered its stake in shares of Eli Lilly And Co (NYSE:LLY) by 2.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 119,400,804 shares of the company’s stock after selling 2,650,000 shares during the period. Eli Lilly And Co accounts for 100.0% of Lilly Endowment Inc.’s investment portfolio, making the stock its biggest holding. Lilly Endowment Inc. owned approximately 11.12% of Eli Lilly And Co worth $12,812,900,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently modified their holdings of the company. FMR LLC increased its stake in shares of Eli Lilly And Co by 172.9% during the 2nd quarter. FMR LLC now owns 1,188,301 shares of the company’s stock worth $101,398,000 after purchasing an additional 752,864 shares during the last quarter. Greenleaf Trust increased its stake in shares of Eli Lilly And Co by 37.7% during the 2nd quarter. Greenleaf Trust now owns 9,815 shares of the company’s stock worth $838,000 after purchasing an additional 2,686 shares during the last quarter. Raymond James & Associates increased its stake in shares of Eli Lilly And Co by 13.4% during the 2nd quarter. Raymond James & Associates now owns 434,915 shares of the company’s stock worth $37,112,000 after purchasing an additional 51,504 shares during the last quarter. Intrust Bank NA grew its stake in Eli Lilly And Co by 6.5% in the 2nd quarter. Intrust Bank NA now owns 9,849 shares of the company’s stock valued at $840,000 after buying an additional 597 shares in the last quarter. Finally, Twin Tree Management LP grew its stake in Eli Lilly And Co by 97.9% in the 2nd quarter. Twin Tree Management LP now owns 1,589 shares of the company’s stock valued at $136,000 after buying an additional 786 shares in the last quarter. Institutional investors own 76.56% of the company’s stock.

Eli Lilly And Co stock traded down $0.26 during mid-day trading on Tuesday, reaching $115.20. The company’s stock had a trading volume of 49,896 shares, compared to its average volume of 4,181,113. Eli Lilly And Co has a 12-month low of $73.69 and a 12-month high of $116.61. The firm has a market capitalization of $115.25 billion, a price-to-earnings ratio of 26.79, a P/E/G ratio of 1.88 and a beta of 0.29. The company has a current ratio of 1.40, a quick ratio of 1.09 and a debt-to-equity ratio of 0.79.

Eli Lilly And Co (NYSE:LLY) last announced its quarterly earnings results on Tuesday, July 24th. The company reported $1.50 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.30 by $0.20. Eli Lilly And Co had a negative net margin of 0.60% and a positive return on equity of 39.84%. The firm had revenue of $6.36 billion during the quarter, compared to the consensus estimate of $6.05 billion. During the same period last year, the firm earned $1.11 EPS. The business’s quarterly revenue was up 9.1% compared to the same quarter last year. On average, equities research analysts forecast that Eli Lilly And Co will post 5.47 EPS for the current year.

In other Eli Lilly And Co news, major shareholder Eli & Co Lilly sold 4,531 shares of the firm’s stock in a transaction on Monday, August 13th. The shares were sold at an average price of $14.33, for a total value of $64,929.23. Following the completion of the transaction, the insider now directly owns 3,934,137 shares of the company’s stock, valued at approximately $56,376,183.21. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Lilly Endowment Inc sold 185,000 shares of the firm’s stock in a transaction on Tuesday, July 24th. The shares were sold at an average price of $92.03, for a total transaction of $17,025,550.00. Following the completion of the transaction, the insider now directly owns 121,631,601 shares of the company’s stock, valued at $11,193,756,240.03. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,770,943 shares of company stock valued at $178,470,135. Insiders own 0.11% of the company’s stock.

LLY has been the subject of a number of recent research reports. BMO Capital Markets lifted their price objective on shares of Eli Lilly And Co from $78.00 to $80.00 and gave the company a “$89.43” rating in a research note on Thursday, July 19th. TheStreet upgraded shares of Eli Lilly And Co from a “c+” rating to a “b” rating in a research note on Friday, June 29th. Cowen set a $105.00 price objective on shares of Eli Lilly And Co and gave the company a “buy” rating in a research note on Tuesday, July 24th. Cantor Fitzgerald set a $100.00 price objective on shares of Eli Lilly And Co and gave the company a “buy” rating in a research note on Tuesday, July 24th. Finally, Zacks Investment Research upgraded shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $100.00 price objective for the company in a research note on Wednesday, July 18th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and twelve have assigned a buy rating to the company. Eli Lilly And Co has a consensus rating of “Buy” and an average price target of $106.06.

Eli Lilly And Co Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

See Also: Find a Trading Strategy That Works

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply